Topic: Genetic Testing

A discussion on PCR testing highlights that the presence of viral DNA does not necessarily indicate active disease or infectiousness. The segment suggests that most people exposed to COVID-19 reach homeostasis after a "genetic update" and remain asymptomatic. Critics argue that using PCR as a primary diagnostic tool for determining COVID-19 deaths is flawed due to these biological factors.

A 2019 clip of Bill Gates discussing CRISPR technology is used to explore the shift in terminology from "strains" to "variants." The hosts suggest that the use of mRNA technology and PCR testing is being leveraged to maintain high case numbers by identifying common cold mutations as COVID-19.

The End User License Agreement (EULA) for AncestryDNA is scrutinized for clauses that grant the company a perpetual, royalty-free, worldwide license to use a customer's DNA data. The discussion highlights that after three years, users may lose certain claims to the ownership of their test results while the company retains usage rights.

The National Institutes of Health (NIH) is promoting the "All of Us" research program, which seeks to collect DNA, blood, and urine samples from one million Americans. While Director Francis Collins assures the public that the data is anonymized and secure, skeptics point to the recent use of genealogical DNA to catch the Golden State Killer as a precedent for law enforcement accessing such databases.

The FDA has approved 23andMe to provide direct-to-consumer genetic testing for three specific mutations linked to breast and ovarian cancer. Dr. David Agus warns that while these tests are now affordable, they only cover a fraction of the over 1,000 possible mutations in the BRCA1 and BRCA2 genes. A negative result on a 23andMe test may provide a false sense of security for individuals who carry other high-risk mutations.

NBC's Kate Snow reports on a woman who underwent a double mastectomy after a $249 DNA test from Color Genomics revealed a BRCA1 mutation. The segment questions the "Wild West" nature of the growing genetic testing industry and the role of "unpaid advisors" in promoting these services. Critics worry that testing without a family history of cancer may lead to unnecessary and extreme medical procedures based on statistical likelihoods.

The FDA issued a warning letter to genetic testing company 23andMe, effectively halting its health-related diagnostic services. The hosts discuss the regulatory conflict, noting that the FDA views the saliva collection kit as an unapproved medical device. They argue that the company's marketing of disease risk, such as BRCA mutations, is misleading without professional genetic counseling.

Angelina Jolie's announcement of a preventive double mastectomy due to the BRCA1 gene mutation is analyzed as a potential PR move for the genetic testing industry. The discussion links the timing of her New York Times op-ed to provisions in the Affordable Care Act that cover such procedures and genetic sequencing.